SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Madrigal Pharmaceuticals
An SI Board Since April 2018
Posts SubjectMarks Bans Symbol
138 9 0 MDGL
Emcee:  Lynn Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
88What about second part, GLP-1 agonist? Is that most prospective NASH compound, aMiljenko Zuanic-4/4/2019
87HbA1c >=9% suggests a compliance problem, so it's probably a good idea toDewDiligence_on_SI-4/4/2019
86Why they are excluding diabetic population: <Exclusion Criteria: History of sMiljenko Zuanic-4/4/2019
85Trial did started at single site, S. Antonio, Texas: clinicaltrials.govMiljenko Zuanic-4/4/2019
84By-the-way, why they need 300 subjects in placebo arm? Are they suspect high levMiljenko Zuanic-3/29/2019
83From the patent applications database I think that they did upgraded large scaleMiljenko Zuanic-3/29/2019
82Are you suggesting their pace of manufacturing will slow down the trials? That tuck-3/28/2019
81Something like that. About 32 months from fist subject dosed, if all go accordinMiljenko Zuanic-3/28/2019
80Does this mean the last of the 900 pts would get first biopsy/dose in 18 months keokalani'nui-3/28/2019
79For now, it is only *plan* to lunch.... finance.yahoo.com If 18 months for firsMiljenko Zuanic-3/28/2019
78They promises nothing.....<and we expect to initiate our Phase 3 clinical triMiljenko Zuanic-2/28/2019
77You may be right, but it is hard for me to believe this team would make a 30-daykeokalani'nui-2/27/2019
7610K (4Q): <Further, we have initiated a Phase 1 hepatic impairment study whicMiljenko Zuanic-2/27/2019
75miserable results for selonsertib (GILD)...... businesswire.comscaram(o)uche-2/11/2019
74HealthCor Management discloses 5.2% stake. (Art Cohen)scaram(o)uche-2/8/2019
73RE: VKTX JPM tidbits....now they are planing (6 additional subjects) to completMiljenko Zuanic-1/8/2019
72cnbc.com IMO, it is not NASH who will dictate market dynamic in future. It may Miljenko Zuanic-12/31/2018
71What was 'suggested" acquisition price for MDGL, by SI experts, 450????Miljenko Zuanic-12/24/2018
70Who is FUCxxx-up (and who not) at MDGL????Miljenko Zuanic-12/20/2018
692809 is at P2b, without small or large animal tox data. VKTX was CHEATING its InMiljenko Zuanic-12/3/2018
68FDA releases draft guidance for NASH drug development (h/t Andy Biotech): Noncituck-12/3/2018
67It is early stage, multiple *inflammatory* conditions/indications. I still thinkMiljenko Zuanic-11/28/2018
66Jecure? businesswire.comdna_joe-11/28/2018
65Friedman went for another 4K shares @ 117, obviously acquisition is not an optioMiljenko Zuanic-11/26/2018
64What a Fxxxx LOSERS!Miljenko Zuanic-11/20/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News